response_type,drug,Primary Tumor type,association,genes,mutation
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK L1152R
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,ALK FUSION G1202R
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,ALK FUSION G1202R
missense_variant,N-acetyl-L-arginine,non-small cell lung carcinoma (disease),Sensitivity,ALK,ALK FUSION G1202R
missense_variant,ALECTINIB,cancer,resistant,ALK,ALK FUSION G1202R
missense_variant,BRIGATINIB,cancer,resistant,ALK,ALK FUSION G1202R
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),resistant,ALK,ALK FUSION G1202R
missense_variant,CRIZOTINIB,lung adenocarcinoma,resistant,ALK,ALK FUSION G1202R
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,ALK FUSION G1202R
missense_variant,CRIZOTINIB,cancer,resistant,ALK,ALK FUSION F1245C
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,ALK FUSION F1245C
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,ALK FUSION F1245C
missense_variant,CRIZOTINIB,neuroblastoma,resistant,ALK,F1245C
missense_variant,LORLATINIB,neuroblastoma,Sensitivity,ALK,F1245C
missense_variant,CRIZOTINIB,lung large cell carcinoma,resistant,ALK,F1174L
missense_variant,CRIZOTINIB,neuroblastoma,resistant,ALK,F1174L
missense_variant,CRIZOTINIB,neuroblastoma,resistant,ALK,F1174L
missense_variant,CRIZOTINIB,neuroblastoma,Sensitivity,ALK,F1174L
missense_variant,LORLATINIB,neuroblastoma,Sensitivity,ALK,F1174L
missense_variant,CRIZOTINIB,inflammatory myofibroblastic tumor,resistant,ALK,F1174L
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,F1174L
missense_variant,ALECTINIB,neuroblastoma,Sensitivity,ALK,F1174L
missense_variant,CRIZOTINIB,neuroblastoma,Sensitivity,ALK,F1174L
missense_variant,CRIZOTINIB,neuroblastoma,resistant,ALK,F1174L
missense_variant,CRIZOTINIB,lung adenocarcinoma,resistant,ALK,HIP1-ALK I1171N
missense_variant,CRIZOTINIB,anaplastic large cell lymphoma,resistant,ALK,HIP1-ALK I1171N
missense_variant,ALECTINIB,non-small cell lung carcinoma (disease),resistant,ALK,HIP1-ALK I1171N
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,HIP1-ALK I1171N
missense_variant,CRIZOTINIB,lung adenocarcinoma,resistant,ALK,EML4-ALK C1156Y
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK C1156Y
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK C1156Y
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK C1156Y
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK C1156Y
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK C1156Y
missense_variant,LORLATINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,EML4-ALK C1156Y
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK C1156Y
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK C1156Y
missense_variant,CRIZOTINIB,neuroblastoma,Sensitivity,ALK,R1275Q
missense_variant,CRIZOTINIB,neuroblastoma,Sensitivity,ALK,R1275Q
missense_variant,LORLATINIB,neuroblastoma,Sensitivity,ALK,R1275Q
missense_variant,CRIZOTINIB,neuroblastoma,Sensitivity,ALK,R1275Q
missense_variant,CRIZOTINIB,neuroblastoma,Sensitivity,ALK,R1275Q
missense_variant,CRIZOTINIB,neuroblastoma,Sensitivity,ALK,R1275Q
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK S1206Y
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,EML4-ALK S1206Y
missense_variant,CERITINIB,cancer,Sensitivity,ALK,EML4-ALK S1206Y
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK S1206Y
missense_variant,CRIZOTINIB,lung large cell carcinoma,resistant,ALK,EML4-ALK I1171S
missense_variant,ALECTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK I1171S
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK I1171S
missense_variant,CRIZOTINIB,anaplastic large cell lymphoma,resistant,ALK,ALK FUSION I1171
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,ALK FUSION I1171
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,ALK FUSION I1171
missense_variant,ALECTINIB,non-small cell lung carcinoma (disease),resistant,ALK,ALK FUSION I1171
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,ALK FUSION I1171
missense_variant,ALECTINIB,non-small cell lung carcinoma (disease),resistant,ALK,ALK FUSION I1171
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,ALK FUSION I1171
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,ALK FUSION I1171
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,ALK FUSION I1171
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK L1196M
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK L1196M
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK L1196M
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK L1196M
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK L1196M
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK L1196M
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK L1196M
missense_variant,CRIZOTINIB,lung adenocarcinoma,resistant,ALK,EML4-ALK L1196M
missense_variant,CRIZOTINIB,lung adenocarcinoma,resistant,ALK,EML4-ALK L1196M
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,EML4-ALK L1196M
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,EML4-ALK L1196M
missense_variant,ALECTINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,EML4-ALK L1196M
missense_variant,ALECTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK  V1180L
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,EML4-ALK  V1180L
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK  V1180L
missense_variant,BRIGATINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,EML4-ALK  V1180L
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),Sensitivity,ALK,ALK FUSION G1269A
missense_variant,CERITINIB,cancer,Sensitivity,ALK,ALK FUSION G1269A
missense_variant,BRIGATINIB,cancer,Sensitivity,ALK,ALK FUSION G1269A
missense_variant,ALECTINIB,cancer,resistant,ALK,ALK FUSION G1269A
missense_variant,CRIZOTINIB,lung large cell carcinoma,resistant,ALK,EML4-ALK G1269A
missense_variant,CRIZOTINIB,lung adenocarcinoma,resistant,ALK,EML4-ALK G1269A
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK G1269A
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK G1269A
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK G1269A
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK G1269A
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ALK,EML4-ALK G1269A
missense_variant,VEMURAFENIB,melanoma (disease),resistant,AKT1,Q79K
missense_variant,VEMURAFENIB,melanoma (disease),resistant,AKT1,Q79K
missense_variant,VEMURAFENIB,melanoma (disease),resistant,AKT1,E17K
missense_variant,Uprosertib,melanoma (disease),Sensitivity,AKT1,E17K
missense_variant,Capivasertib,breast cancer,Sensitivity,AKT1,E17K
missense_variant,Sorafenib,non-small cell lung carcinoma (disease),Sensitivity,ARAF,S214C
missense_variant,TRAMETINIB,non-small cell lung carcinoma (disease),Sensitivity,ARAF,S214C
missense_variant,Sorafenib,non-small cell lung carcinoma (disease),Sensitivity,ARAF,S214C
missense_variant,Irinotecan,colorectal cancer,resistant,ARAF,S490T
missense_variant,VEMURAFENIB,colorectal cancer,resistant,ARAF,S490T
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E355G
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E355G
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E355G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL E355G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E355G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E355G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL E355G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL E355G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T315A
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317S
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Q252H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Q252H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Q252H
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Q252H
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Q252H
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Q252H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Q252H
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Q252H
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Q252H
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Q252H
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Q252H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317I
missense_variant,DASATINIB,acute lymphoblastic leukemia (disease),resistant,ABL1,BCR-ABL F317I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL L387M
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL L387M
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL L387M
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,N336S
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,N336S
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E453Q
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,D421G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,E292V
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,E292V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,V299L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,V299L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,V299L
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,V299L
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,V299L
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,V299L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317C
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E255K
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E255K
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E255K
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E255K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL E255K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL E255K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL E255K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL E255K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL E255K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL E255K
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E255K
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E255K
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E255K
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E255K
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E255K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253H
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253H
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253H
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Y253H
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Y253H
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Y253H
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,PONATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL T334I
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,PONATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL T334I
missense_variant,PONATINIB,acute lymphoblastic leukemia (disease),Sensitivity,ABL1,BCR-ABL T334I
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL T334I
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL T334I
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL T334I
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL T334I
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,acute lymphoblastic leukemia (disease),resistant,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,acute lymphoblastic leukemia (disease),resistant,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,acute lymphoblastic leukemia (disease),resistant,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,acute lymphoblastic leukemia (disease),resistant,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,acute lymphoblastic leukemia (disease),resistant,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,acute lymphoblastic leukemia (disease),resistant,ABL1,BCR-ABL T334I
missense_variant,DASATINIB,acute lymphoblastic leukemia (disease),resistant,ABL1,BCR-ABL T334I
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E453K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL E453K
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL L364P
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,L298V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L298V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL F486S
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F486S
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F486S
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL F486S
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253F
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253F
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Y253F
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253F
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253F
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253F
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253F
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Y253F
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Y253F
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Y253F
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,Y253F
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F311I
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F311I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL F311I
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F311I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359C
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359C
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359C
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359C
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359C
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,F359C
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E459K
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E459K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E459K
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL V379I
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL V379I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL V379I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL V379I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL V379I
missense_variant,DASATINIB,acute lymphoblastic leukemia (disease),Sensitivity/Response,ABL1,BCR-ABL V379I
missense_variant,Imatinib,non-small cell lung carcinoma (disease),Sensitivity/Response,ABL1,R351W
missense_variant,DASATINIB,non-small cell lung carcinoma (disease),Sensitivity/Response,ABL1,R351W
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL N331S
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL N331S
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317V
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E453A
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E453A
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL A397P
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL A397P
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL A397P
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,DASATINIB,acute lymphoblastic leukemia (disease),resistant,ABL1,BCR-ABL F317L
missense_variant,PONATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL F317L
missense_variant,PONATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL F317L
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL F317L
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F317L
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F311L
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F311L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL F311L
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F311L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL F311L
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,M351T
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M351T
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,L384M
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,L384M
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,L384M
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L384M
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L384M
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F359I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F359I
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F359I
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F359I
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL F359I
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL F359I
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL H396P
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL H396P
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL H396P
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL H396P
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL H396P
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL H396P
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL H396P
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L248V
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L248V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L248V
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L248V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L248V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L248V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L248V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Q300R
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,Q300R
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL L248R
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL L248R
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL L248R
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,G250E
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,G250E
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,G250E
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,G250E
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,G250E
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,G250E
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,G250E
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,G250E
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,G250E
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,G250E
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,G250E
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,G250E
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,G250E
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,G250E
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,G250E
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,E279K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,E279K
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,E279K
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,M244V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,D276G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,D276G
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,D276G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,D276G
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,D276G
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,D276G
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,D276G
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,D276G
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,D276G
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,L387F
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,L387F
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,L387F
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359V
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,F359V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,F359V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,F359V
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,F359V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,F359V
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,F359V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,H396R
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,H396R
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,H396R
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,H396R
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,H396R
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,H396R
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,H396R
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,H396R
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,H396R
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,H396R
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,H396R
missense_variant,Imatinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,H396R
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL P480A
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,E255V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,E255V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,E255V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,E255V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,E255V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,E255V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,E255V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,E255V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,E255V
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,E255V
missense_variant,AXITINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,E255V
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,E255V
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,E255V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,ABL1,BCR-ABL E450V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,ABL1,BCR-ABL E450V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL G398R
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL G398R
missense_variant,NILOTINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,ABL1,BCR-ABL G398R
missense_variant,TRAMETINIB,cutaneous melanoma (disease),Sensitivity,BRAF,L597R
missense_variant,VEMURAFENIB,cutaneous melanoma (disease),Sensitivity,BRAF,L597R
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,L597R
missense_variant,VEMURAFENIB,cancer,Sensitivity/Response,BRAF,G596R
missense_variant,VEMURAFENIB,colorectal cancer,resistant,BRAF,G596R
missense_variant,TRAMETINIB,cutaneous melanoma (disease),Sensitivity,BRAF,L597V
missense_variant,TRAMETINIB,cutaneous melanoma (disease),Sensitivity,BRAF,L597Q
missense_variant,VEMURAFENIB,cutaneous melanoma (disease),Sensitivity,BRAF,L597Q
missense_variant,malathion,cutaneous melanoma (disease),Sensitivity,BRAF,L597S
missense_variant,TRAMETINIB,cutaneous melanoma (disease),Sensitivity,BRAF,L597S
missense_variant,VEMURAFENIB,cutaneous melanoma (disease),Sensitivity,BRAF,L597S
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600D
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600D
missense_variant,DABRAFENIB,melanoma (disease),Sensitivity,BRAF,V600D
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,DABRAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,TRAMETINIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,DABRAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,COBIMETINIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600K
missense_variant,DABRAFENIB,cutaneous melanoma (disease),Sensitivity,BRAF,K601E
missense_variant,TRAMETINIB,cutaneous melanoma (disease),Sensitivity,BRAF,K601E
missense_variant,VEMURAFENIB,cutaneous melanoma (disease),Sensitivity,BRAF,K601E
missense_variant,VEMURAFENIB,cancer,Sensitivity/Response,BRAF,G469A
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,BRAF,G469A
missense_variant,VEMURAFENIB,melanoma (disease),resistant,BRAF,G469A
missense_variant,VEMURAFENIB,cancer,Sensitivity/Response,BRAF,G466V
missense_variant,VEMURAFENIB,melanoma (disease),resistant,BRAF,V600E
missense_variant,Sorafenib,colorectal cancer,resistant,BRAF,V600E
missense_variant,DABRAFENIB,non-small cell lung carcinoma (disease),resistant,BRAF,V600E
missense_variant,DABRAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,TRAMETINIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,PLX-4720,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,PICTILISIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,PLX-4720,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,CAPECITABINE,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,TRAMETINIB,melanoma (disease),resistant,BRAF,V600E
missense_variant,PD-0325901,melanoma (disease),resistant,BRAF,V600E
missense_variant,VEMURAFENIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,PICTILISIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,DASATINIB,melanoma (disease),resistant,BRAF,V600E
missense_variant,VEMURAFENIB,thyroid cancer,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,non-small cell lung carcinoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,malignant glioma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,malignant glioma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,malignant glioma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,malignant glioma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,hairy cell leukemia,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,hairy cell leukemia,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,hairy cell leukemia,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,hairy cell leukemia,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,hairy cell leukemia,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,glioma susceptibility 1,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,pilocytic astrocytoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,thyroid gland papillary carcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,thyroid gland papillary carcinoma,Sensitivity,BRAF,V600E
missense_variant,DASATINIB,thyroid gland papillary carcinoma,Sensitivity,BRAF,V600E
missense_variant,REGORAFENIB,colon carcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,ganglioglioma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,ganglioglioma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,clear cell sarcoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,lung adenocarcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,lung adenocarcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,lung adenocarcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,lung adenocarcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,Thyroid Carcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,Thyroid Carcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,pleomorphic xanthoastrocytoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,ovarian cystadenocarcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,malignant peripheral nerve sheath tumor,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,histiocytoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,malignant conjunctival melanoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,DABRAFENIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,GEFITINIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,cutaneous melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,cutaneous melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,TRAMETINIB,cutaneous melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,DABRAFENIB,cutaneous melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,thyroid gland papillary carcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,COBIMETINIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,Nevirapine,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,DACTOLISIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,DABRAFENIB,"digestive system neuroendocrine tumor, grade 1/2",Sensitivity,BRAF,V600E
missense_variant,TRAMETINIB,"digestive system neuroendocrine tumor, grade 1/2",Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,"digestive system neuroendocrine tumor, grade 1/2",Sensitivity,BRAF,V600E
missense_variant,SELUMETINIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,Nevirapine,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,DACTOLISIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,hairy cell leukemia,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,thyroid gland papillary carcinoma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,plasma cell myeloma,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,plasma cell myeloma,Sensitivity,BRAF,V600E
missense_variant,COBIMETINIB,cancer,Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,VEMURAFENIB,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,Irinotecan,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,FLUOROURACIL,colorectal cancer,resistant,BRAF,V600E
missense_variant,Irinotecan,colorectal cancer,resistant,BRAF,V600E
missense_variant,Irinotecan,colorectal cancer,resistant,BRAF,V600E
missense_variant,Sorafenib,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,Sorafenib,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,PD-0325901,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,PD-0325901,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,DABRAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,DABRAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,DABRAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,SELUMETINIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,SELUMETINIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,DABRAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,DABRAFENIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,TRAMETINIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,TRAMETINIB,melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,CI-1040,thyroid cancer,Sensitivity,BRAF,V600E
missense_variant,CI-1040,thyroid cancer,Sensitivity,BRAF,V600E
missense_variant,CI-1040,thyroid cancer,Sensitivity,BRAF,V600E
missense_variant,Refametinib,thyroid cancer,Sensitivity,BRAF,V600E
missense_variant,Refametinib,thyroid cancer,Sensitivity,BRAF,V600E
missense_variant,Refametinib,thyroid cancer,Sensitivity,BRAF,V600E
missense_variant,Sorafenib,thyroid cancer,Sensitivity,BRAF,V600E
missense_variant,PD-0325901,non-small cell lung carcinoma (disease),Sensitivity,BRAF,V600E
missense_variant,SELUMETINIB,malignant glioma,Sensitivity,BRAF,V600E
missense_variant,SELUMETINIB,malignant glioma,Sensitivity,BRAF,V600E
missense_variant,DABRAFENIB,cutaneous melanoma (disease),Sensitivity,BRAF,V600E
missense_variant,Sorafenib,thyroid cancer,Sensitivity,BRAF,V600E
missense_variant,Sorafenib,thyroid cancer,Sensitivity,BRAF,V600E
missense_variant,Sorafenib,colorectal cancer,Sensitivity,BRAF,V600E
missense_variant,DABRAFENIB,non-small cell lung carcinoma (disease),Sensitivity,BRAF,V600E
missense_variant,TRAMETINIB,non-small cell lung carcinoma (disease),Sensitivity,BRAF,V600E
missense_variant,Sorafenib,cutaneous melanoma (disease),Sensitivity,BRAF,D594A
missense_variant,VEMURAFENIB,cancer,Sensitivity/Response,BRAF,N581S
missense_variant,Sorafenib,cutaneous melanoma (disease),Sensitivity,BRAF,K483M
missense_variant,VEMURAFENIB,cancer,Sensitivity/Response,BRAF,G606E
missense_variant,Sorafenib,cutaneous melanoma (disease),Sensitivity/Response,BRAF,G469E
missense_variant,TRAMETINIB,cutaneous melanoma (disease),Sensitivity,BRAF,D594V
missense_variant,Sorafenib,cutaneous melanoma (disease),Sensitivity,BRAF,D594V
missense_variant,VEMURAFENIB,cancer,Sensitivity/Response,BRAF,G464V
missense_variant,Sorafenib,breast cancer,Sensitivity/Response,BRAF,G464V
missense_variant,TRAMETINIB,non-small cell lung carcinoma (disease),Sensitivity,BRAF,G596C
missense_variant,DABRAFENIB,non-small cell lung carcinoma (disease),Sensitivity,BRAF,G596C
missense_variant,VEMURAFENIB,cancer,Sensitivity/Response,BRAF,P731T
missense_variant,VEMURAFENIB,melanoma (disease),resistant,BRAF,L505H
missense_variant,VEMURAFENIB,melanoma (disease),resistant,BRAF,L505H
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA1,E1559K
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA1,C64Y
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA1,D1692N
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA1,C61G
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA1,R71G
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA1,R1495M
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA1,R71K
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA2,V211L
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA2,M1I
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA2,R2336H
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA2,V211I
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA2,V159M
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA2,M1R
missense_variant,RUCAPARIB,ovarian cancer,Sensitivity/Response,BRCA2,R2336P
missense_variant,PALBOCICLIB,cutaneous melanoma (disease),Sensitivity,CDK4,R24C
missense_variant,DAUNORUBICIN,acute myeloid leukemia,resistant,DNMT3A,R882
missense_variant,Idarubicin,acute myeloid leukemia,Sensitivity,DNMT3A,R882
missense_variant,Erlotinib,lung adenocarcinoma,Sensitivity,EGFR,E746G
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity/Response,EGFR,K806E
missense_variant,Erlotinib,malignant glioma,Sensitivity/Response,EGFR,A289V
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,G719A
missense_variant,Erlotinib,lung adenocarcinoma,Sensitivity,EGFR,G719A
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,G719A
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,G719A
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity/Response,EGFR,A864T
missense_variant,GEFITINIB,lung cancer,resistant,EGFR,T790M
missense_variant,AEE-788,lung cancer,resistant,EGFR,T790M
missense_variant,ROCILETINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,DACOMITINIB,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,PEMETREXED,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,Staurosporine,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,OSIMERTINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,Erlotinib,lung adenocarcinoma,resistant,EGFR,T790M
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,OSIMERTINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,OSIMERTINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,OSIMERTINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,OSIMERTINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,ROCILETINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,EGFR,T790M
missense_variant,GEFITINIB,lung adenocarcinoma,resistant,EGFR,T790M
missense_variant,Erlotinib,lung adenocarcinoma,resistant,EGFR,T790M
missense_variant,ROCILETINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,OSIMERTINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,AFATINIB,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,OSIMERTINIB,lung adenocarcinoma,Sensitivity,EGFR,T790M
missense_variant,AFATINIB,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,OSIMERTINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,OSIMERTINIB,lung adenocarcinoma,Sensitivity,EGFR,T790M
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,Lapatinib,non-small cell lung carcinoma (disease),resistant,EGFR,T790M
missense_variant,DACOMITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,NERATINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,AFATINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,AFATINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,CANERTINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,OSIMERTINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,BRIGATINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,T790M
missense_variant,Erlotinib,malignant glioma,Sensitivity/Response,EGFR,T263P
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,EGFR,D761Y
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),resistant,EGFR,D761Y
missense_variant,Erlotinib,lung adenocarcinoma,Sensitivity/Response,EGFR,K757R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,G719S
missense_variant,Erlotinib,lung adenocarcinoma,Sensitivity,EGFR,G719S
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,G719S
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,G719S
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,G719S
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,G719S
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,G719S
missense_variant,Erlotinib,malignant mesothelioma (disease),Sensitivity/Response,EGFR,E734Q
missense_variant,Erlotinib,lung adenocarcinoma,resistant,EGFR,S768I
missense_variant,Erlotinib,lung adenocarcinoma,resistant,EGFR,S768I
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,S768I
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,S768I
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,S768I
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,S768I
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,S768I
missense_variant,GEFITINIB,lung adenocarcinoma,Sensitivity,EGFR,S768I
missense_variant,Erlotinib,lung adenocarcinoma,Sensitivity,EGFR,S768I
missense_variant,BRIGATINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,C797S
missense_variant,OSIMERTINIB,lung adenocarcinoma,resistant,EGFR,C797S
missense_variant,OSIMERTINIB,non-small cell lung carcinoma (disease),resistant,EGFR,C797S
missense_variant,Erlotinib,malignant mesothelioma (disease),Sensitivity/Response,EGFR,C797Y
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity/Response,EGFR,R831H
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity/Response,EGFR,R831H
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity/Response,EGFR,R831H
missense_variant,Erlotinib,malignant mesothelioma (disease),Sensitivity/Response,EGFR,R831H
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity/Response,EGFR,V851I
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,AFATINIB,lung adenocarcinoma,Sensitivity,EGFR,L858R
missense_variant,AFATINIB,lung adenocarcinoma,Sensitivity,EGFR,L858R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,AFATINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,AFATINIB,lung adenocarcinoma,Sensitivity,EGFR,L858R
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,GEFITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,Lapatinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,DACOMITINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,NERATINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,AFATINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,AFATINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,CANERTINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,GEFITINIB,lung adenocarcinoma,Sensitivity,EGFR,L858R
missense_variant,GEFITINIB,lung adenocarcinoma,Sensitivity,EGFR,L858R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,EGFR,L858R
missense_variant,Erlotinib,lung adenocarcinoma,Sensitivity,EGFR,L858R
missense_variant,Erlotinib,lung adenocarcinoma,Sensitivity,EGFR,L858R
missense_variant,Erlotinib,lung adenocarcinoma,Sensitivity,EGFR,L858R
missense_variant,Erlotinib,malignant glioma,Sensitivity,EGFR,L858R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,AFATINIB,non-small cell lung carcinoma (disease),Sensitivity,EGFR,L858R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,EGFR,N826S
missense_variant,NERATINIB,breast cancer,Sensitivity,ERBB2,L755W
missense_variant,Lapatinib,hepatocellular carcinoma,Sensitivity,ERBB2,H878Y
missense_variant,NERATINIB,breast cancer,Sensitivity,ERBB2,D769Y
missense_variant,Lapatinib,ovarian cancer,Sensitivity,ERBB2,N857S
missense_variant,Lapatinib,gastric carcinoma,Sensitivity,ERBB2,T862A
missense_variant,Lapatinib,breast cancer,resistant,ERBB2,L755S
missense_variant,Lapatinib,colon carcinoma,Sensitivity,ERBB2,L755S
missense_variant,NERATINIB,colon carcinoma,Sensitivity,ERBB2,L755S
missense_variant,Lapatinib,breast cancer,resistant,ERBB2,L755S
missense_variant,NERATINIB,breast cancer,Sensitivity,ERBB2,L755S
missense_variant,Lapatinib,breast cancer,Sensitivity,ERBB2,R678Q
missense_variant,NERATINIB,breast cancer,Sensitivity,ERBB2,R678Q
missense_variant,NERATINIB,colon carcinoma,Sensitivity,ERBB2,L866M
missense_variant,Lapatinib,colon carcinoma,Sensitivity,ERBB2,L866M
missense_variant,NERATINIB,breast cancer,Sensitivity,ERBB2,R896C
missense_variant,Lapatinib,colon carcinoma,Sensitivity,ERBB2,V842I
missense_variant,NERATINIB,colon carcinoma,Sensitivity,ERBB2,V842I
missense_variant,NERATINIB,breast cancer,Sensitivity,ERBB2,V842I
missense_variant,NERATINIB,breast cancer,Sensitivity,ERBB2,D769H
missense_variant,NERATINIB,breast cancer,Sensitivity,ERBB2,G309A
missense_variant,Lapatinib,colon carcinoma,Sensitivity,ERBB2,V777L
missense_variant,NERATINIB,colon carcinoma,Sensitivity,ERBB2,V777L
missense_variant,NERATINIB,breast cancer,Sensitivity,ERBB2,V777L
missense_variant,Lapatinib,head and neck squamous cell carcinoma,Sensitivity,ERBB2,V773A
missense_variant,Lapatinib,colon carcinoma,Sensitivity,ERBB2,S310F/Y
missense_variant,NERATINIB,colon carcinoma,Sensitivity,ERBB2,S310F/Y
missense_variant,PALBOCICLIB,breast cancer,Sensitivity,ESR1,Y537S
missense_variant,PALBOCICLIB,breast cancer,Sensitivity,ESR1,Y537S
missense_variant,FULVESTRANT,breast cancer,Sensitivity,ESR1,Y537S
missense_variant,Tamoxifen,breast cancer,Sensitivity,ESR1,Y537S
missense_variant,PALBOCICLIB,breast cancer,Sensitivity,ESR1,Y537N
missense_variant,PALBOCICLIB,breast cancer,Sensitivity,ESR1,Y537N
missense_variant,FULVESTRANT,breast cancer,Sensitivity,ESR1,Y537N
missense_variant,Tamoxifen,breast cancer,Sensitivity,ESR1,Y537N
missense_variant,PALBOCICLIB,breast cancer,Sensitivity,ESR1,Y537C
missense_variant,FULVESTRANT,breast cancer,Sensitivity,ESR1,Y537C
missense_variant,Tamoxifen,breast cancer,Sensitivity,ESR1,Y537C
missense_variant,FULVESTRANT,breast cancer,Sensitivity,ESR1,L536Q
missense_variant,Tamoxifen,breast cancer,Sensitivity,ESR1,L536Q
missense_variant,PALBOCICLIB,breast cancer,Sensitivity,ESR1,S463P
missense_variant,PALBOCICLIB,breast cancer,Sensitivity,ESR1,D538G
missense_variant,PALBOCICLIB,breast cancer,Sensitivity,ESR1,D538G
missense_variant,FULVESTRANT,breast cancer,Sensitivity,ESR1,D538G
missense_variant,Tamoxifen,breast cancer,Sensitivity,ESR1,D538G
missense_variant,PAZOPANIB,bladder urachal urothelial carcinoma,Sensitivity,FGFR3,S249C
missense_variant,SUNITINIB,acute myeloid leukemia,Sensitivity,FLT3,D835H
missense_variant,SUNITINIB,acute myeloid leukemia,Sensitivity,FLT3,D835H
missense_variant,Sorafenib,acute myeloid leukemia,resistant,FLT3,D835H
missense_variant,Sorafenib,acute myeloid leukemia,resistant,FLT3,D835H/Y
missense_variant,SUNITINIB,acute myeloid leukemia,Sensitivity/Response,FLT3,D835V
missense_variant,SUNITINIB,acute myeloid leukemia,Sensitivity/Response,FLT3,D835V
missense_variant,SUNITINIB,acute myeloid leukemia,Sensitivity/Response,FLT3,D835V
missense_variant,QUIZARTINIB,acute myeloid leukemia,Sensitivity/Response,FLT3,D835V
missense_variant,DAUNORUBICIN,acute myeloid leukemia,Sensitivity/Response,FLT3,D835V
missense_variant,SUNITINIB,acute myeloid leukemia,Sensitivity/Response,FLT3,D835V
missense_variant,SUNITINIB,acute myeloid leukemia,Sensitivity/Response,FLT3,D835V
missense_variant,SUNITINIB,acute myeloid leukemia,Sensitivity/Response,FLT3,D835V
missense_variant,SUNITINIB,acute myeloid leukemia,resistant,FLT3,D835V
missense_variant,Ivosidenib,acute myeloid leukemia,Sensitivity,IDH1,R132C
missense_variant,TEMOZOLOMIDE,brain glioma,Sensitivity,IDH1,R132C
missense_variant,TEMOZOLOMIDE,brain glioma,Sensitivity,IDH1,R132C
missense_variant,TEMOZOLOMIDE,brain glioma,Sensitivity,IDH1,R132C
missense_variant,TEMOZOLOMIDE,brain glioma,Sensitivity,IDH1,R132S
missense_variant,Ivosidenib,acute myeloid leukemia,Sensitivity,IDH1,R132S
missense_variant,TEMOZOLOMIDE,brain glioma,Sensitivity,IDH1,R132S
missense_variant,TEMOZOLOMIDE,brain glioma,Sensitivity,IDH1,R132S
missense_variant,TEMOZOLOMIDE,brain glioma,Sensitivity,IDH1,R132L
missense_variant,Ivosidenib,acute myeloid leukemia,Sensitivity,IDH1,R132L
missense_variant,TEMOZOLOMIDE,brain glioma,Sensitivity,IDH1,R132L
missense_variant,TEMOZOLOMIDE,brain glioma,Sensitivity,IDH1,R132L
missense_variant,TEMOZOLOMIDE,brain glioma,Sensitivity,IDH1,R132H
missense_variant,Fedratinib,acquired polycythemia vera,Sensitivity,JAK2,V617F
missense_variant,DASATINIB,melanoma (disease),Sensitivity,KIT,K642E
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity,KIT,K642E
missense_variant,SUNITINIB,gastrointestinal stromal tumor,Sensitivity,KIT,K642E
missense_variant,Imatinib,cancer,Sensitivity/Response,KIT,N822K
missense_variant,Imatinib,acute myeloid leukemia,Sensitivity/Response,KIT,N822K
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,KIT,N822K
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,resistant,KIT,N822K
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,KIT,N822K
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,resistant,KIT,N822K
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,KIT,N822K
missense_variant,Imatinib,cancer,resistant,KIT,N822H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,KIT,V654A
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,KIT,V654A
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,resistant,KIT,V654A
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,KIT,V654A
missense_variant,SUNITINIB,gastrointestinal stromal tumor,Sensitivity,KIT,V654A
missense_variant,Imatinib,chronic leukemia,Sensitivity,KIT,M541L
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,KIT,L576P
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity,KIT,L576P
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity,KIT,L576P
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity,KIT,L576P
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,KIT,L576P
missense_variant,DASATINIB,melanoma (disease),Sensitivity,KIT,L576P
missense_variant,NILOTINIB,non-small cell lung carcinoma (disease),Sensitivity,KIT,L576P
missense_variant,Imatinib,non-small cell lung carcinoma (disease),Sensitivity,KIT,L576P
missense_variant,DASATINIB,non-small cell lung carcinoma (disease),Sensitivity,KIT,L576P
missense_variant,Sorafenib,melanoma (disease),resistant,KIT,L576P
missense_variant,NILOTINIB,melanoma (disease),resistant,KIT,L576P
missense_variant,Imatinib,melanoma (disease),resistant,KIT,L576P
missense_variant,Imatinib,gastrointestinal stromal tumor,Sensitivity,KIT,L576P
missense_variant,Imatinib,gastrointestinal stromal tumor,Sensitivity,KIT,L576P
missense_variant,Imatinib,gastrointestinal stromal tumor,Sensitivity,KIT,L576P
missense_variant,DASATINIB,melanoma (disease),Sensitivity,KIT,L576P
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,KIT,D820G
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,resistant,KIT,D820G
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,KIT,T670I
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,resistant,KIT,T670I
missense_variant,DASATINIB,cancer,resistant,KIT,T670I
missense_variant,Imatinib,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V559D
missense_variant,SUNITINIB,cancer,Sensitivity/Response,KIT,V559D
missense_variant,SUNITINIB,cancer,Sensitivity/Response,KIT,V559D
missense_variant,Imatinib,cancer,Sensitivity/Response,KIT,V559D
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,KIT,V559D
missense_variant,DASATINIB,cancer,Sensitivity/Response,KIT,V559D
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,KIT,V559D
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V559D
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V559D
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V559D
missense_variant,DASATINIB,melanoma (disease),Sensitivity/Response,KIT,V559D
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,KIT,V559D
missense_variant,Imatinib,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V559D
missense_variant,Sorafenib,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V559D
missense_variant,NILOTINIB,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V559D
missense_variant,DASATINIB,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V559D
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity/Response,KIT,N822K
missense_variant,Imatinib,acute myeloid leukemia,resistant,KIT,D816H
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,KIT,D816H
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,KIT,D816H
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,resistant,KIT,D816H
missense_variant,SUNITINIB,gastrointestinal stromal tumor,Sensitivity/Response,KIT,D816H
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,KIT,D816H
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,KIT,C809G
missense_variant,Imatinib,melanoma (disease),resistant,KIT,D820Y
missense_variant,Imatinib,cancer,resistant,KIT,V560G
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,KIT,V560G
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V560G
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V560G
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V560G
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,KIT,V560G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,KIT,V560G
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity/Response,KIT,V560G
missense_variant,Imatinib,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V560G
missense_variant,Imatinib,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V560G
missense_variant,Imatinib,gastrointestinal stromal tumor,Sensitivity/Response,KIT,V560G
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,KIT,D816V
missense_variant,DASATINIB,"chronic myelogenous leukemia, BCR-ABL1 positive",Sensitivity,KIT,D816V
missense_variant,Bosutinib,"chronic myelogenous leukemia, BCR-ABL1 positive",resistant,KIT,D816V
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,KIT,D816V
missense_variant,DASATINIB,acute myeloid leukemia,Sensitivity,KIT,D816V
missense_variant,MIDOSTAURIN,systemic mastocytosis,Sensitivity,KIT,D816V
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,KIT,Y823D
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,KIT,D820A
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,resistant,KIT,D820A
missense_variant,SELUMETINIB,non-small cell lung carcinoma (disease),Sensitivity,KRAS,G12V
missense_variant,PALBOCICLIB,non-small cell lung carcinoma (disease),Sensitivity,KRAS,G12V
missense_variant,REGORAFENIB,colorectal cancer,resistant,KRAS,G12V
missense_variant,SUNITINIB,colorectal cancer,resistant,KRAS,G12V
missense_variant,PALBOCICLIB,colorectal cancer,Sensitivity,KRAS,G12V
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12V
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12V
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12V
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12V
missense_variant,REGORAFENIB,colon carcinoma,Sensitivity,KRAS,G12V
missense_variant,CRIZOTINIB,cancer,resistant,KRAS,G12V
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12V
missense_variant,Nevirapine,non-small cell lung carcinoma (disease),Sensitivity,KRAS,G12D
missense_variant,DACTOLISIB,non-small cell lung carcinoma (disease),Sensitivity,KRAS,G12D
missense_variant,VEMURAFENIB,hairy cell leukemia,resistant,KRAS,G12D
missense_variant,REGORAFENIB,colorectal cancer,resistant,KRAS,G12D
missense_variant,REGORAFENIB,colorectal cancer,resistant,KRAS,G12D
missense_variant,SUNITINIB,colorectal cancer,resistant,KRAS,G12D
missense_variant,Erlotinib,lung cancer,resistant,KRAS,G12D
missense_variant,Erlotinib,lung cancer,resistant,KRAS,G12D
missense_variant,Erlotinib,lung cancer,resistant,KRAS,G12D
missense_variant,Erlotinib,lung cancer,resistant,KRAS,G12D
missense_variant,Erlotinib,lung cancer,resistant,KRAS,G12D
missense_variant,Erlotinib,lung cancer,resistant,KRAS,G12D
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12D
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12D
missense_variant,VEMURAFENIB,melanoma (disease),resistant,KRAS,G12D
missense_variant,VEMURAFENIB,exocrine pancreatic carcinoma,resistant,KRAS,G12D
missense_variant,VEMURAFENIB,skin squamous cell carcinoma,resistant,KRAS,G12D
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12D
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12D
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12D
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12D
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12D
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12D
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12D
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12D
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12D
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12D
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12D
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12D
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12D
missense_variant,SELUMETINIB,non-small cell lung carcinoma (disease),Sensitivity,KRAS,G12C
missense_variant,GEFITINIB,colorectal cancer,resistant,KRAS,G12C
missense_variant,Erlotinib,colorectal cancer,resistant,KRAS,G12C
missense_variant,REGORAFENIB,colorectal cancer,resistant,KRAS,G12C
missense_variant,SUNITINIB,colorectal cancer,resistant,KRAS,G12C
missense_variant,PALBOCICLIB,colorectal cancer,Sensitivity,KRAS,G12C
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12C
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12C
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12C
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12C
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,KRAS,G12C
missense_variant,VEMURAFENIB,skin squamous cell carcinoma,resistant,KRAS,G12C
missense_variant,CRIZOTINIB,lung adenocarcinoma,resistant,KRAS,G12C
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12C
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12C
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12C
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12C
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12C
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12C
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12C
missense_variant,REGORAFENIB,colorectal cancer,resistant,KRAS,G12A
missense_variant,SUNITINIB,colorectal cancer,resistant,KRAS,G12A
missense_variant,Erlotinib,lung cancer,resistant,KRAS,G12A
missense_variant,Erlotinib,lung cancer,resistant,KRAS,G12A
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12A
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12A
missense_variant,REGORAFENIB,non-small cell lung carcinoma (disease),Sensitivity,KRAS,G12A
missense_variant,GEFITINIB,lung adenocarcinoma,resistant,KRAS,G12A
missense_variant,Erlotinib,lung adenocarcinoma,resistant,KRAS,G12A
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12A
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12A
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12A
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12A
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12A
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12A
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12A
missense_variant,Abemaciclib,non-small cell lung carcinoma (disease),Sensitivity,KRAS,A146V
missense_variant,REGORAFENIB,colorectal cancer,resistant,KRAS,G12S
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12S
missense_variant,SUNITINIB,colorectal cancer,resistant,KRAS,G12S
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12S
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12S
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12S
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12S
missense_variant,VEMURAFENIB,non-small cell lung carcinoma (disease),resistant,KRAS,G12S
missense_variant,DASATINIB,squamous cell lung carcinoma,resistant,KRAS,G12S
missense_variant,GEFITINIB,lung cancer,resistant,KRAS,G12S
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12S
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12S
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12S
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12S
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12S
missense_variant,MELPHALAN,plasma cell myeloma,resistant,KRAS,G12S
missense_variant,Erlotinib,lung cancer,resistant,KRAS,Q61H
missense_variant,VEMURAFENIB,non-small cell lung carcinoma (disease),resistant,KRAS,Q61H
missense_variant,TRAMETINIB,colorectal cancer,resistant,KRAS,Q61H
missense_variant,Irinotecan,colorectal cancer,resistant,KRAS,Q61H
missense_variant,REGORAFENIB,colorectal cancer,resistant,KRAS,G12R
missense_variant,SUNITINIB,colorectal cancer,resistant,KRAS,G12R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12R
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,KRAS,G12R
missense_variant,DASATINIB,thyroid cancer,Sensitivity,KRAS,G12R
missense_variant,VEMURAFENIB,Thyroid Carcinoma,resistant,KRAS,G12R
missense_variant,PD-0325901,colorectal cancer,Sensitivity,KRAS,A146T
missense_variant,Irinotecan,colorectal cancer,resistant,KRAS,A146T
missense_variant,Irinotecan,colorectal cancer,resistant,MAP2K1,C121S
missense_variant,VEMURAFENIB,colorectal cancer,resistant,MAP2K1,C121S
missense_variant,VEMURAFENIB,melanoma (disease),resistant,MAP2K1,C121S
missense_variant,VEMURAFENIB,melanoma (disease),resistant,MAP2K1,Q56P
missense_variant,SELUMETINIB,melanoma (disease),resistant,MAP2K1,Q56P
missense_variant,SELUMETINIB,lung adenocarcinoma,Sensitivity,MAP2K1,K57N
missense_variant,SELUMETINIB,melanoma (disease),resistant,MAP2K1,P124S
missense_variant,SELUMETINIB,cutaneous melanoma (disease),Sensitivity,NRAS,Q61
missense_variant,BINIMETINIB,cutaneous melanoma (disease),Sensitivity,NRAS,Q61
missense_variant,VEMURAFENIB,melanoma (disease),resistant,NRAS,Q61
missense_variant,SELUMETINIB,colorectal cancer,Sensitivity/Response,NRAS,G12D
missense_variant,Nevirapine,colorectal cancer,Sensitivity/Response,NRAS,G12D
missense_variant,DACTOLISIB,colorectal cancer,Sensitivity/Response,NRAS,G12D
missense_variant,SELUMETINIB,colorectal cancer,Sensitivity/Response,NRAS,G12D
missense_variant,Nevirapine,colorectal cancer,Sensitivity/Response,NRAS,G12D
missense_variant,DACTOLISIB,colorectal cancer,Sensitivity/Response,NRAS,G12D
missense_variant,Nevirapine,colorectal cancer,Sensitivity/Response,NRAS,G12D
missense_variant,DACTOLISIB,colorectal cancer,Sensitivity/Response,NRAS,G12D
missense_variant,VEMURAFENIB,Thyroid Carcinoma,resistant,NRAS,Q61R
missense_variant,VEMURAFENIB,cutaneous melanoma (disease),resistant,NRAS,Q61R
missense_variant,VEMURAFENIB,melanoma (disease),resistant,NRAS,Q61R
missense_variant,SELUMETINIB,non-small cell lung carcinoma (disease),Sensitivity,NRAS,Q61R
missense_variant,TRAMETINIB,non-small cell lung carcinoma (disease),Sensitivity,NRAS,Q61R
missense_variant,Nevirapine,colorectal cancer,Sensitivity,NRAS,Q61R
missense_variant,Nevirapine,colorectal cancer,Sensitivity,NRAS,Q61R
missense_variant,Nevirapine,colorectal cancer,Sensitivity,NRAS,Q61R
missense_variant,TEMOZOLOMIDE,melanoma (disease),Sensitivity,NRAS,Q61R
missense_variant,VEMURAFENIB,melanoma (disease),resistant,NRAS,Q61L
missense_variant,VEMURAFENIB,melanoma (disease),resistant,NRAS,Q61L
missense_variant,SELUMETINIB,non-small cell lung carcinoma (disease),Sensitivity,NRAS,Q61L
missense_variant,TRAMETINIB,non-small cell lung carcinoma (disease),Sensitivity,NRAS,Q61L
missense_variant,Nevirapine,colorectal cancer,Sensitivity,NRAS,Q61L
missense_variant,Nevirapine,colorectal cancer,Sensitivity,NRAS,Q61L
missense_variant,Nevirapine,colorectal cancer,Sensitivity,NRAS,Q61L
missense_variant,TEMOZOLOMIDE,melanoma (disease),Sensitivity,NRAS,Q61L
missense_variant,N-acetyl-L-arginine,melanoma (disease),Sensitivity,NRAS,G13D
missense_variant,BINIMETINIB,neuroblastoma,Sensitivity,NRAS,Q61K
missense_variant,VEMURAFENIB,melanoma (disease),resistant,NRAS,Q61K
missense_variant,VEMURAFENIB,melanoma (disease),resistant,NRAS,Q61K
missense_variant,VEMURAFENIB,melanoma (disease),resistant,NRAS,Q61K
missense_variant,VEMURAFENIB,cutaneous melanoma (disease),resistant,NRAS,Q61K
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),resistant,NRAS,Q61K
missense_variant,VEMURAFENIB,cutaneous melanoma (disease),resistant,NRAS,Q61K
missense_variant,SELUMETINIB,cutaneous melanoma (disease),Sensitivity,NRAS,Q61K
missense_variant,Nevirapine,colorectal cancer,Sensitivity,NRAS,Q61K
missense_variant,Nevirapine,colorectal cancer,Sensitivity,NRAS,Q61K
missense_variant,Nevirapine,colorectal cancer,Sensitivity,NRAS,Q61K
missense_variant,Nevirapine,colorectal cancer,Sensitivity,NRAS,Q61K
missense_variant,SELUMETINIB,non-small cell lung carcinoma (disease),Sensitivity,NRAS,Q61K
missense_variant,TRAMETINIB,non-small cell lung carcinoma (disease),Sensitivity,NRAS,Q61K
missense_variant,SELUMETINIB,lung cancer,Sensitivity,NRAS,Q61K
missense_variant,TRAMETINIB,lung cancer,Sensitivity,NRAS,Q61K
missense_variant,IDELALISIB,Merkel Cell Carcinoma,Sensitivity,PIK3CA,P471L
missense_variant,VEMURAFENIB,melanoma (disease),resistant,PIK3CA,E545K
missense_variant,PICTILISIB,cervical carcinoma,Sensitivity,PIK3CA,E545K
missense_variant,ASPIRIN,colorectal cancer,Sensitivity,PIK3CA,E545K
missense_variant,Adenosine,breast cancer,Sensitivity,PIK3CA,E545K
missense_variant,ASPIRIN,colorectal cancer,Sensitivity,PIK3CA,E545K
missense_variant,APITOLISIB,cancer,Sensitivity,PIK3CA,E545K
missense_variant,AFATINIB,lung adenocarcinoma,resistant,PIK3CA,E545K
missense_variant,Erlotinib,lung adenocarcinoma,resistant,PIK3CA,E545K
missense_variant,GEFITINIB,lung adenocarcinoma,resistant,PIK3CA,E545K
missense_variant,GEFITINIB,lung adenocarcinoma,resistant,PIK3CA,E545K
missense_variant,PICTILISIB,breast cancer,Sensitivity,PIK3CA,E545K
missense_variant,CH5132799,breast cancer,Sensitivity,PIK3CA,E542K
missense_variant,APITOLISIB,head and neck squamous cell carcinoma,Sensitivity,PIK3CA,E542K
missense_variant,ASPIRIN,colorectal cancer,Sensitivity,PIK3CA,E542K
missense_variant,ASPIRIN,colorectal cancer,Sensitivity,PIK3CA,E542K
missense_variant,CH5132799,breast cancer,Sensitivity,PIK3CA,H1047R
missense_variant,VEMURAFENIB,colorectal cancer,resistant,PIK3CA,H1047R
missense_variant,Nevirapine,head and neck cancer,Sensitivity,PIK3CA,H1047R
missense_variant,DACTOLISIB,head and neck cancer,Sensitivity,PIK3CA,H1047R
missense_variant,ALPELISIB,head and neck cancer,Sensitivity,PIK3CA,H1047R
missense_variant,Nevirapine,lung adenocarcinoma,Sensitivity,PIK3CA,H1047R
missense_variant,DACTOLISIB,lung adenocarcinoma,Sensitivity,PIK3CA,H1047R
missense_variant,TASELISIB,head and neck squamous cell carcinoma,Sensitivity,PIK3CA,H1047R
missense_variant,Capivasertib,Her2-receptor Positive Breast Cancer,Sensitivity,PIK3CA,H1047R
missense_variant,Capivasertib,Her2-receptor Positive Breast Cancer,Sensitivity,PIK3CA,H1047R
missense_variant,Lapatinib,Her2-receptor Positive Breast Cancer,Sensitivity,PIK3CA,H1047R
missense_variant,Nevirapine,head and neck cancer,Sensitivity,PIK3CA,H1047R
missense_variant,DACTOLISIB,head and neck cancer,Sensitivity,PIK3CA,H1047R
missense_variant,Nevirapine,head and neck cancer,Sensitivity,PIK3CA,H1047R
missense_variant,DACTOLISIB,head and neck cancer,Sensitivity,PIK3CA,H1047R
missense_variant,FULVESTRANT,Her2-receptor Positive Breast Cancer,Sensitivity,PIK3CA,H1047R
missense_variant,Adenosine,breast cancer,Sensitivity,PIK3CA,H1047R
missense_variant,ASPIRIN,colorectal cancer,Sensitivity,PIK3CA,H1047R
missense_variant,ASPIRIN,colorectal cancer,Sensitivity,PIK3CA,H1047R
missense_variant,VEMURAFENIB,melanoma (disease),resistant,PIK3CA,E545G
missense_variant,PICTILISIB,breast cancer,Sensitivity/Response,PIK3CA,E545G
missense_variant,PICTILISIB,breast cancer,Sensitivity/Response,PIK3CA,E545G
missense_variant,VEMURAFENIB,melanoma (disease),resistant,PIK3CA,D350G
missense_variant,CRENOLANIB,gastrointestinal stromal tumor,Sensitivity,PDGFRA,D842I
missense_variant,Imatinib,melanoma (disease),Sensitivity,PDGFRA,G853D
missense_variant,CRENOLANIB,melanoma (disease),Sensitivity,PDGFRA,G853D
missense_variant,CRENOLANIB,gastrointestinal stromal tumor,Sensitivity,PDGFRA,D842Y
missense_variant,Imatinib,melanoma (disease),Sensitivity,PDGFRA,H845Y
missense_variant,CRENOLANIB,melanoma (disease),Sensitivity,PDGFRA,H845Y
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,PDGFRA,D842V
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,PDGFRA,D842V
missense_variant,SUNITINIB,gastrointestinal stromal tumor,resistant,PDGFRA,D842V
missense_variant,DASATINIB,gastrointestinal stromal tumor,Sensitivity,PDGFRA,D842V
missense_variant,CRENOLANIB,gastrointestinal stromal tumor,Sensitivity,PDGFRA,D842V
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,PDGFRA,D842V
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,PDGFRA,D842V
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,PDGFRA,D842V
missense_variant,Imatinib,gastrointestinal stromal tumor,resistant,PDGFRA,D842V
missense_variant,Imatinib,cancer,resistant,PDGFRA,V561D
missense_variant,Imatinib,gastrointestinal stromal tumor,Sensitivity/Response,PDGFRA,V561D
missense_variant,SUNITINIB,gastrointestinal stromal tumor,Sensitivity/Response,PDGFRA,V561D
missense_variant,Imatinib,gastrointestinal stromal tumor,Sensitivity,PDGFRA,V561A
missense_variant,Imatinib,melanoma (disease),Sensitivity,PDGFRA,R841K
missense_variant,CRENOLANIB,melanoma (disease),Sensitivity,PDGFRA,R841K
missense_variant,Imatinib,melanoma (disease),Sensitivity,PDGFRA,P577S
missense_variant,CRENOLANIB,melanoma (disease),Sensitivity,PDGFRA,P577S
missense_variant,DASATINIB,chronic eosinophilic leukemia,resistant,PDGFRA,FIP1L1-PDGFRA T674I
missense_variant,Imatinib,"myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1",resistant,PDGFRA,FIP1L1-PDGFRA T674I
missense_variant,PONATINIB,"myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1",Sensitivity,PDGFRA,FIP1L1-PDGFRA T674I
missense_variant,D-Allopyranose,acute promyelocytic leukemia,resistant,PML,PML-RARA A216V
missense_variant,D-Allopyranose,acute promyelocytic leukemia,resistant,PML,PML-RARA L218P
missense_variant,REGORAFENIB,gastrointestinal stromal tumor,Sensitivity,RET,C634W
missense_variant,AXITINIB,Thyroid Medullary Carcinoma,resistant,RET,C634W
missense_variant,MOTESANIB,Thyroid Medullary Carcinoma,resistant,RET,C634W
missense_variant,AXITINIB,Thyroid Medullary Carcinoma,resistant,RET,M918T
missense_variant,Sorafenib,Thyroid Medullary Carcinoma,Sensitivity,RET,M918T
missense_variant,MOTESANIB,Thyroid Medullary Carcinoma,resistant,RET,M918T
missense_variant,AZD-1480,Thyroid Medullary Carcinoma,Sensitivity,RET,M918T
missense_variant,Phosphorylcolamine,gastric carcinoma,Sensitivity,TP53,R213P
missense_variant,Phosphorylcolamine,gastric carcinoma,Sensitivity,TP53,R282L
missense_variant,Phosphorylcolamine,gastric carcinoma,Sensitivity,TP53,R273C
missense_variant,Phosphorylcolamine,gastric carcinoma,Sensitivity,TP53,Y220C
missense_variant,Phosphorylcolamine,gastric carcinoma,Sensitivity,TP53,R175H
missense_variant,Doxorubicin,breast cancer,Sensitivity,TP53,R175H
missense_variant,DASATINIB,non-small cell lung carcinoma (disease),Sensitivity,DDR2,I638F
missense_variant,DASATINIB,non-small cell lung carcinoma (disease),Sensitivity,DDR2,L239R
missense_variant,DASATINIB,non-small cell lung carcinoma (disease),Sensitivity,DDR2,L63V
missense_variant,DASATINIB,non-small cell lung carcinoma (disease),Sensitivity,DDR2,G253C
missense_variant,Erlotinib,non-small cell lung carcinoma (disease),Sensitivity,DDR2,S768R
missense_variant,DASATINIB,non-small cell lung carcinoma (disease),Sensitivity,DDR2,S768R
missense_variant,DASATINIB,non-small cell lung carcinoma (disease),Sensitivity,DDR2,G505S
missense_variant,DASATINIB,non-small cell lung carcinoma (disease),Sensitivity,DDR2,G774V
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,MET,D1228N
missense_variant,CABOZANTINIB,non-small cell lung carcinoma (disease),Sensitivity,MET,D1228V
missense_variant,SAVOLITINIB,non-small cell lung carcinoma (disease),resistant,MET,D1228V
missense_variant,SUNITINIB,von Hippel-Lindau disease,Sensitivity/Response,VHL,N78S (c.233A>G)
missense_variant,RUXOLITINIB,Chuvash polycythemia,Sensitivity,VHL,R200W (c.598C>T)
missense_variant,IBRUTINIB,B-cell chronic lymphocytic leukemia,resistant,BTK,T316A
missense_variant,IBRUTINIB,B-cell chronic lymphocytic leukemia,resistant,BTK,C481S
missense_variant,IBRUTINIB,B-cell chronic lymphocytic leukemia,resistant,BTK,C481S
missense_variant,ENZALUTAMIDE,prostate cancer,resistant,AR,F877L
missense_variant,BICALUTAMIDE,prostate carcinoma,resistant,AR,W742
missense_variant,OLAPARIB,prostate cancer,Sensitivity,ATM,N2875H
missense_variant,AMRUBICIN,lung cancer,Sensitivity,NQO1,P187S
missense_variant,AFATINIB,bladder urachal urothelial carcinoma,Sensitivity,ERBB3,V104M
missense_variant,AFATINIB,non-small cell lung carcinoma (disease),Sensitivity,ERBB3,V855A
missense_variant,AFATINIB,bladder urachal urothelial carcinoma,Sensitivity,ERBB3,R103G
missense_variant,AFATINIB,bladder urachal urothelial carcinoma,Sensitivity,ERBB3,G284R
missense_variant,PONATINIB, "Bone Ewing's Sarcoma",Sensitivity,FGFR1,N546K
missense_variant,LY-294002,melanoma (disease),Sensitivity,MTOR,P2213S
missense_variant,Capivasertib,melanoma (disease),Sensitivity,MTOR,P2213S
missense_variant,AZD-8055,breast cancer,resistant,MTOR,M2327I
missense_variant,AZD-8055,breast cancer,resistant,MTOR,A2034V
missense_variant,Capivasertib,melanoma (disease),Sensitivity,MTOR,H1968Y
missense_variant,Capivasertib,melanoma (disease),Sensitivity,MTOR,H1968Y
missense_variant,LY-294002,melanoma (disease),Sensitivity,MTOR,H1968Y
missense_variant,SELUMETINIB,uveal melanoma,Sensitivity,GNA11,Q209
missense_variant,PLX-4720,cutaneous melanoma (disease),resistant,GNAQ,Q209P
missense_variant,VEMURAFENIB,cutaneous melanoma (disease),resistant,GNAQ,Q209P
missense_variant,Irinotecan,colorectal cancer,resistant,GNAS,R201C
missense_variant,VEMURAFENIB,colorectal cancer,resistant,GNAS,R201C
missense_variant,VEMURAFENIB,skin squamous cell carcinoma,resistant,HRAS,G13D
missense_variant,RUXOLITINIB,hepatocellular carcinoma,Sensitivity,JAK1,S703I
missense_variant,Sorafenib,pediatric angiosarcoma,Sensitivity,KDR,A1065T
missense_variant,SUNITINIB,pediatric angiosarcoma,Sensitivity,KDR,A1065T
missense_variant,Sorafenib,pediatric angiosarcoma,Sensitivity,KDR,D717V
missense_variant,SUNITINIB,pediatric angiosarcoma,Sensitivity,KDR,D717V
missense_variant,REGORAFENIB,colorectal adenocarcinoma,Sensitivity,KDR,R961W
missense_variant,FLUOROURACIL,rectal cancer,Sensitivity,MTHFR,A222V
missense_variant,FLUOROURACIL,gastric carcinoma,Sensitivity,MTHFR,A222V
missense_variant,IBRUTINIB, "Waldenstr?m's Macroglobulinemia",Sensitivity,MYD88,L265P
missense_variant,ENTRECTINIB,breast cancer,resistant,NTRK3,ETV6-NTRK3 G623R
missense_variant,Erlotinib,head and neck squamous cell carcinoma,Sensitivity,MAPK1,E322K
missense_variant,Erlotinib,head and neck squamous cell carcinoma,Sensitivity,MAPK1,E322K
missense_variant,VEMURAFENIB,melanoma (disease),resistant,RAC1,P29S
missense_variant,DABRAFENIB,melanoma (disease),resistant,RAC1,P29S
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ROS1,CD74-ROS1 G2101A
missense_variant,FORETINIB,non-small cell lung carcinoma (disease),Sensitivity,ROS1,CD74-ROS1 G2101A
missense_variant,FORETINIB,non-small cell lung carcinoma (disease),resistant,ROS1,CD74-ROS1 L2155S
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ROS1,CD74-ROS1 L2155S
missense_variant,LORLATINIB,non-small cell lung carcinoma (disease),Sensitivity,ROS1,CD74-ROS1 G2032R
missense_variant,CERITINIB,non-small cell lung carcinoma (disease),resistant,ROS1,CD74-ROS1 G2032R
missense_variant,BRIGATINIB,non-small cell lung carcinoma (disease),resistant,ROS1,CD74-ROS1 G2032R
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ROS1,CD74-ROS1 G2032R
missense_variant,CABOZANTINIB,non-small cell lung carcinoma (disease),Sensitivity,ROS1,CD74-ROS1 G2032R
missense_variant,FORETINIB,non-small cell lung carcinoma (disease),Sensitivity,ROS1,CD74-ROS1 G2032R
missense_variant,FORETINIB,non-small cell lung carcinoma (disease),Sensitivity,ROS1,CD74-ROS1 G2032R
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ROS1,CD74-ROS1 G2032R
missense_variant,CABOZANTINIB,non-small cell lung carcinoma (disease),Sensitivity,ROS1,CD74-ROS1 G2032R
missense_variant,CRIZOTINIB,lung adenocarcinoma,resistant,ROS1,CD74-ROS1 G2032R
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ROS1,G2032R
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ROS1,G2032R
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ROS1,G2032R
missense_variant,CRIZOTINIB,lung adenocarcinoma,resistant,ROS1,G2032R
missense_variant,FORETINIB,non-small cell lung carcinoma (disease),Sensitivity,ROS1,CD74-ROS1 L2026M
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ROS1,CD74-ROS1 L2026M
missense_variant,LORLATINIB,non-small cell lung carcinoma (disease),Sensitivity,ROS1,CD74-ROS1 L2026M
missense_variant,CRIZOTINIB,non-small cell lung carcinoma (disease),resistant,ROS1,CD74-ROS1 L2026M
missense_variant,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,L412F
missense_variant,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,L412F
missense_variant,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,L412F
missense_variant,VISMODEGIB,medulloblastoma,resistant,SMO,D473H
missense_variant,SARIDEGIB,medulloblastoma,Sensitivity,SMO,D473H
missense_variant,VISMODEGIB,skin basal cell carcinoma,resistant,SMO,D473H
missense_variant,VISMODEGIB,medulloblastoma,resistant,SMO,D473H
missense_variant,Gemcitabine,non-small cell lung carcinoma (disease),Sensitivity,XRCC1,R194W
missense_variant,VEMURAFENIB,melanoma (disease),resistant,AKT3,E17K
missense_variant,THIOGUANINE,T-cell acute lymphoblastic leukemia,resistant,NT5C2,R367Q
missense_variant,NELARABINE,T-cell acute lymphoblastic leukemia,resistant,NT5C2,R367Q
missense_variant,THIOGUANINE,T-cell acute lymphoblastic leukemia,resistant,NT5C2,D407A
missense_variant,NELARABINE,T-cell acute lymphoblastic leukemia,resistant,NT5C2,D407A
missense_variant,THIOGUANINE,T-cell acute lymphoblastic leukemia,resistant,NT5C2,K359Q
missense_variant,NELARABINE,T-cell acute lymphoblastic leukemia,resistant,NT5C2,K359Q
missense_variant,Ethanol,colorectal cancer,Sensitivity,PPP1R15A,RS557806
